Menu Search
Equities

Apollon Formularies PLC

73R:STU

Apollon Formularies PLC

Actions
  • Price (EUR)0.0005
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-50.00%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Apollon Formularies plc is a United Kingdom-based medical cannabis pharmaceutical company. The Company is engaged in specializing in research and treatment of patients with cancer and chronic pain. The Company has hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products. Its products with trademarks include APOLLON-Full Extract Cannabis Oil (FECO) Vape, APOLLON FECO Oral Tincture-30ml Bottle, and APOLLON FECO Prescribed Capsules. It also includes Apollon NAUSEA Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER. It offers services, including cultivation, processing and extraction, international cancer institute, retail product sales, Apollon Negril facility, research and development, and bespoke treatments and products. The Company’s wholly owned subsidiary is Apollon Formularies Ltd.

  • Revenue in GBP (TTM)--
  • Net income in GBP--
  • Incorporated2008
  • Employees18.00
  • Location
    Apollon Formularies PLCSte 3b, 38 Jermyn StreetLONDON SW1Y 6DNUnited KingdomGBR
  • Phone+44 207 440 0640
  • Fax+44 207 440 0641
  • Websitehttps://www.afriagglobal.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.